Show simple item record

dc.contributor.authorXie, Wei
dc.contributor.authorMondragon, Laura
dc.contributor.authorMauseth, Brynjar
dc.contributor.authorWang, Yan
dc.contributor.authorPol, Jonathan
dc.contributor.authorLevesque, Sarah
dc.contributor.authorZhou, Heng
dc.contributor.authorYamazaki, Takahiro
dc.contributor.authorEksteen, Jacobus Johannes
dc.contributor.authorZitvogel, Laurence
dc.contributor.authorSveinbjørnsson, Baldur
dc.contributor.authorRekdal, Øystein
dc.contributor.authorKepp, Oliver
dc.contributor.authorKroemer, Guido
dc.date.accessioned2020-04-01T11:13:39Z
dc.date.available2020-04-01T11:13:39Z
dc.date.issued2019-04-13
dc.description.abstractLocal immunotherapies such as the intratumoral injection of oncolytic compounds aim at reinstating and enhancing systemic anticancer immune responses. LTX-315 is a first-in-class, clinically evaluated oncolytic peptide-based local immunotherapy that meets these criteria. Here, we show that LTX-401, yet another oncolytic compound designed for local immunotherapy, depicts a similar safety profile and that sequential local inoculation of LTX-401 was able to cure immunocompetent host from subcutaneous MCA205 and TC-1 cancers. Cured animals exhibited long-term immune memory effects that rendered them resistant to rechallenge with syngeneic tumors. Nevertheless, the local treatment with LTX-401 alone had only limited abscopal effects on secondary contralateral lesions. Anticancer effects resulting from single as well as sequential injections of LTX-401 were boosted in combination with PD-1 and CTLA-4 immune checkpoint blockade (ICB), and sequential LTX-401 treatment combined with double ICB exhibited strong abscopal antineoplastic effects on contralateral tumors underlining the potency of this combination therapy.en_US
dc.descriptionThis is an Accepted Manuscript of an article published by Taylor & Francis in <i>Oncoimmunology</i> on 13 April 2019, available online: <a href=https://www.tandfonline.com/doi/full/10.1080/2162402X.2019.1594555>https://www.tandfonline.com/doi/full/10.1080/2162402X.2019.1594555</a>.en_US
dc.identifier.citationXie W, Mondragon L, Mauseth B, Wang Y, Pol, Levesque, Zhou H, Yamazaki T, Eksteen JJ, Zitvogel L, Sveinbjørnsson B, Rekdal Ø, Kepp O, Kroemer G. Tumor lysis with LTX-401 creates anticancer immunity. Oncoimmunology. 2019;8(7)en_US
dc.identifier.cristinIDFRIDAID 1706784
dc.identifier.doi10.1080/2162402X.2019.1594555
dc.identifier.issn2162-4011
dc.identifier.issn2162-402X
dc.identifier.urihttps://hdl.handle.net/10037/17961
dc.language.isoengen_US
dc.publisherTaylor & Francisen_US
dc.relation.journalOncoimmunology
dc.relation.projectIDinfo:eu-repo/grantAgreement/RCN/BIOTEK2021/254800/Norway/Verifying a New Generation of Oncolytic Peptides as Cancer Immunotherapeutic Agents for Deep-Seated Tumors//en_US
dc.relation.projectIDinfo:eu-repo/grantAgreement/RCN/NAERINGSPH/ 257967/Norway/Investigating a New Generation of Oncolytic Peptides as Cancer Immunotherapeutic Agents for Deep-Seated Tumors//en_US
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2019 Taylor & Francis Group, LLCen_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762en_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en_US
dc.titleTumor lysis with LTX-401 creates anticancer immunityen_US
dc.type.versionacceptedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record